Emerging evidence has suggested that cytoreductive prostatectomy (CRP) allows superior oncologic control when compared to current standard of care androgen deprivation therapy alone. However, the safety and benefit of cytoreduction in metastatic prostate cancer (mPCa) has not been proven. Therefore, we evaluated the incidence of complications following CRP in men newly diagnosed with mPCa. A total of 68 patients who underwent CRP from 2006 to 2014 at four tertiary surgical centers were compared to 598 men who underwent radical prostatectomy for clinically localized prostate cancer (PCa). Urinary incontinence was defined as the use of any pad. CRP had longer operative times (200 min vs 140 min,P< 0.0001) and higher estimated blood loss(250 ml vs 125 ml,P<0.0001)compared to the control group.However,both overall(8.82% vs 5.85%)and major complication rates(4.41% vs 2.17%)were comparable between the two groups.Importantly,urinary incontinence rate at 1?year after surgery was significantly higher in the CRP group(57.4% vs 90.8%,P<0.0001).Univariate logistic analysis showed that the estimated blood loss was the only independent predictor of perioperative complications both in the unadjusted model (OR: 1.18;95% CI: 1.02–1.37; P = 0.025) and surgery type?adjusted model (OR: 1.17; 95% CI: 1.01–1.36; P = 0.034). In conclusion, CRP is more challenging than radical prostatectomy and associated with a notably higher incidence of urinary incontinence. Nevertheless, CRP is a technically feasible and safe surgery for selecting PCa patients who present with node?positive or bony metastasis when performed by experienced surgeons. A prospective, multi?institutional clinical trial is currently underway to verify this concept.